June 24, 2021 in Kineta Press Release

Kineta’s Thierry Guillaudeux Participated on Multiple Panel Presentations During Virtual Symposium on VISTA

Kineta’s Thierry Guillaudeux Participated on Multiple Panel Presentations During Virtual Symposium on VISTA: A New Immunotherapy Approach to Treating Cancer

Seattle, WA — (June 24, 2021) Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, announced today that Thierry Guillaudeux, Ph.D., SVP Immuno-oncology at Kineta, participated on multiple panel presentations during the virtual symposium “VISTA: A New Immune Checkpoint in Cancer, Autoimmunity and Beyond,” that took place on June 18, 2021.

“It was a great pleasure to participate in this symposium focused on VISTA”, said Thierry Guillaudeux of Kineta. “The scientific presentations and discussions from the different panelists clearly emphasized how VISTA is a promising new immuno-oncology target for treating patients with advanced tumors. Its unique mechanism of action involving both an innate and adaptive immune response illustrates that antibody therapy targeting VISTA could be an important new path in cancer treatments with this new generation of checkpoint inhibitors.”

The scientific symposium focused on the emerging checkpoint inhibitor VISTA, its function, the role it plays in several oncology and current development programs. The event was hosted by Randolph Noelle, Ph.D., Professor of Microbiology and Immunology, Department of Microbiology and Immunology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth; and Padmanee Sharma, M.D., Ph.D., Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, University of Texas, MD Anderson Cancer Center.

“Kineta has made tremendous progress developing KVA12.1, our novel anti-VISTA antibody currently in preclinical evaluation”, said Thierry Guillaudeux of Kineta. “We nominated KVA12.1 as our lead clinical candidate earlier this year and have initiated IND enabling studies.  We expect to initiate Phase 1 safety and tolerability studies in mid-2022”.


Kineta, Inc. is a clinical stage biotechnology company committed to developing disruptive life science technologies that address unmet patient needs.  We have leveraged our expertise in immunology to advance a focused pipeline of investigational drugs in oncology and neuroscience.  We actively collaborate with a broad array of private, government and industry partners to advance our innovative products.  For more information on Kineta visit our website, www.kinetabio.com, follow us on Twitter at @kinetabio, LinkedIn and Like us on facebook.com/KinetaBio.

NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding Kineta’s plans for pre-clinical and clinical studies, regulatory filings, investor returns and anticipated drug effects in human subjects. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta’s business which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and Kineta undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.


Contact Jacques Bouchy
(206) 378-0400